The trial, funded by the National Surgical and Adjuvant Bowel and Breast Project, will study whether patients who have had CRC surgically removed can take statins to prevent polyp formation, thereby preventing a recurrence of CRC.
Over five years, the study will compare the effects of the cholesterol-lowering rosuvastatin (Crestor) to a placebo through regular exams and tests. In the last two years, physicians will actively follow -up to monitor CRC recurrence.
Read the release on University of Cincinnati trial.
Read more coverage on colorectal cancer:
– Study: 4% Increase in Hospitals Offering Computed Tomographic Colonography
– AHRQ Highlights Successful Strategies for Increasing CRC Screening, Infection Prevention
– Baylor Health, Eureka Form Alliance for Colorectal Cancer Research
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.